During the past decade, Retina Vitreous Center conducted 14 clinical trials. In the 10-year time frame, 14 clinical trials started and 9 clinical trials were completed, i.e. on average, 64.3% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 7 clinical trials were completed. i.e. 140% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Retina Vitreous Center" #1 sponsor was "Jaeb Center for Health Research" with 7 trials, followed by "Hoffmann-La Roche" with 6 trials sponsored, "Aerpio Therapeutics" with 1 trials sponsored, "Genentech, Inc." with 1 trials sponsored and "Pfizer" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Retina Vitreous Center" #1 collaborator was "National Eye Institute (NEI)" with 6 trials as a collaborator, "National Institutes of Health (NIH)" with 5 trials as a collaborator, "Regeneron Pharmaceuticals" with 3 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator and "Juvenile Diabetes Research Foundation" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Retina Vitreous Center" are "Diabetic Macular Edema" (6 trials), "Diabetic Retinopathy" (2 trials), "Neovascular Age-Related Macular Degeneration" (2 trials), "Age-Related Macular Degeneration" (1 trials) and "Epiretinal Membrane" (1 trials). Many other conditions were trialed in "Retina Vitreous Center" in a lesser frequency.

Most popular intervention types in "Retina Vitreous Center" are "Drug" (11 trials), "Procedure" (4 trials), "Other" (3 trials), "Device" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Faricimab" (2 trials), "Intravitreal Ranibizumab 0.5 mg Injection" (2 trials), "PDS Implant Pre-Filled with 100 mg/mL Ranibizumab" (2 trials) and "Sham Procedure" (2 trials). Other intervention names were less common.

The vast majority of trials in "Retina Vitreous Center" are 16 trials for "All" genders.

Currently, there are NaN active trials in "Retina Vitreous Center". undefined are not yet recruiting, 3 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in Retina Vitreous Center, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Retina Vitreous Center, 1 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".